Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Haemonetics (HAE) EBITDA (2016 - 2025)

Haemonetics has reported EBITDA over the past 17 years, most recently at $67.4 million for Q4 2025.

  • For Q4 2025, EBITDA rose 307.05% year-over-year to $67.4 million; the TTM value through Dec 2025 reached $251.1 million, up 109.64%, while the annual FY2025 figure was $221.8 million, 34.53% up from the prior year.
  • EBITDA for Q4 2025 was $67.4 million at Haemonetics, up from $58.5 million in the prior quarter.
  • Over five years, EBITDA peaked at $71.3 million in Q1 2025 and troughed at -$21.2 million in Q2 2021.
  • A 5-year average of $30.9 million and a median of $30.6 million in 2024 define the central range for EBITDA.
  • Biggest five-year swings in EBITDA: tumbled 181.42% in 2021 and later surged 427.28% in 2022.
  • Year by year, EBITDA stood at $14.4 million in 2021, then skyrocketed by 159.36% to $37.4 million in 2022, then increased by 5.79% to $39.6 million in 2023, then plummeted by 58.15% to $16.6 million in 2024, then surged by 307.05% to $67.4 million in 2025.
  • Business Quant data shows EBITDA for HAE at $67.4 million in Q4 2025, $58.5 million in Q3 2025, and $53.9 million in Q2 2025.